pharmaceuticals to counter osteoporosis and cardiac illness - Florentine pharmaceutical company Stroder will promote and distribute two new drugs in Italy, one against osteoporosis and the other to cure cardiac illnesses.
The drugs were developed and produced by French group Servier but promotional information for doctors and distribution will be done by Stroder - the Italian branch of the Swiss multinational headquartered in Florence.
Stroder works with approximately 80 employees in addition to an external network of scientific researchers all over the country.
Stroder recently launched the 'strontium ranelato', a molecule able to stimulate bone production and combat osteoporosis.
Patented by the Florentine company, the 'strontium ranelato' was called one of the most innovative molecules in recent history by Time magazine.
There are already over 25,000 patients in Italy who take the drug.
Stroder is set to launch another patented molecule on the market, called the 'ivabradina', which yields a pharmaceutical able to act on the IF channels in a pacemaker and slow down heart rates.
Professor Alessandro Mugelli of the University of Florence's pharmacology department participated in the development of the drug.
According to the criteria of the Servier group, 25% of profits from the sale of products go to research activities.
